Draft Medicare coverage for key tests is expected before September 2026, with claim-by-claim reimbursement targeted to drive interim revenue. Cash burn has been reduced, a NZD 24 million capital raise is underway, and commercial payer adoption is advancing, supported by strong clinical evidence and new pilot studies.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.